Shots:
- Biocytogen & Acepodia have entered into a strategic collaboration to evaluate dual-payload bispecific antibody-drug conjugate (BsAD2C) program in complex tumors by combining the former’s RenLite platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) tech
- Under the agreement, Biocytogen will provide a bispecific antibody from its RenLite platform, while Acepodia will combine 2 distinct payloads using its AD2C platform
- The AD2C platform uses bio-orthogonal click chemistry for precise, site-selective payload conjugation without altering antibody integrity, enabling optimal Drug-to-Antibody Ratio (DAR) for potency and safety
Ref: Biocytogen | Image: Acepodia & Biocytogen
Related News:- IDEAYA Amends Clinical Trial Collaboration and Supply Agreements with Pfizer to Evaluate Darovasertib + Crizotinib Combination in 1L Metastatic Uveal Melanoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
